CoChat

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Open access
Mentz, Robert J., Bethel, M. Angelyn, Gustavson, Stephanie, Thompson, Vivian P., Pagidipati, Neha J., Buse, John B., Chan, Juliana C., Iqbal, Nayyar, Maggioni, Aldo P., Marso, Steve P., Ohman, Peter, Poulter, Neil, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F., Holman, Rury R. · 2017 · American Heart Journal
Cited by 64

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background EXSCEL is a randomized, double‐blind, placebo‐controlled trial examining the effect of exenatide once‐weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk. Methods Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) outcomes trials. Results Of a total of 14,752 participants randomized between June 2010 and September 2015, 6,788 (46.0%) patients were enrolled in Europe; 3,708 (25.1%), North America; 2,727 (18.5%), Latin America; and 1,529 (10.4%), Asia Pacific. Overall, 73% had at least one prior CV event (70% coronary artery disease, 24% peripheral arterial disease, 22% cerebrovascular disease). The median (IQR) age was 63 years (56, 69), 38% were female, median baseline HbA1c was 8.0% (7.3, 8.9) and 16% had a prior history of heart failure. Those without a prior CV event were younger with a shorter duration of diabetes and better renal function than those with at least one prior CV event. Compared with prior GLP‐1RA trials, EXSCEL has a larger percentage of patients without a prior CV event and a notable percentage who were taking a dipeptidyl peptidase‐4 inhibitor at baseline (15%). Conclusions EXSCEL is one of the largest global GLP‐1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP‐1RA trials (ClinicalTrials.gov number, NCT01144338).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2017.02.005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 64

Metadata

Authors
Mentz, R. J., Bethel, M. A., Gustavson, S., Thompson, V. P., Pagidipati, N. J., Buse, J. B., Chan, J. C., Iqbal, N., Maggioni, A. P., Marso, S. P., Ohman, P., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A. F., & Holman, R. R.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2017-05
Volume
187
Pages
1-9
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2588615098
Cited by
64
References
8
FWCI
6.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). https://app.cochat.ai/papers/10.1016/j.ahj.2017.02.005
The paper
Mentz, R. J., Bethel, M. A., Gustavson, S., Thompson, V. P., Pagidipati, N. J., Buse, J. B., Chan, J. C., Iqbal, N., Maggioni, A. P., Marso, S. P., Ohman, P., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A. F., & Holman, R. R. (2017). Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). American Heart Journal. https://doi.org/10.1016/j.ahj.2017.02.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.